We utilized a well-validated technology to measure the 78 markers of inflammation and used a novel two-stage design that allowed for the reweighting of the analysis to the population-based PLCO screening arm. While we did not observe significant associations, our results are in agreement with previous studies in similar populations (9, 11, 14, 16, 31).